menu search

POAI / Predictive Oncology launches ACE program to partner with academic and research institutions to advance drug discovery initiatives

Predictive Oncology launches ACE program to partner with academic and research institutions to advance drug discovery initiatives
Predictive Oncology Inc. (NASDAQ:POAI) has announced the launch of ACE (Accelerating Compound Exploration), a program to advance oncology drug development initiatives with academic and research institutions. The Eagan, Minnesota-based company said it created ACE to grant early-stage academic drug development groups and technology transfer offices access to its PEDAL platform. Read More
Posted: Feb 21 2023, 09:52
Author Name: Proactive Investors
Views: 101932

POAI News  

Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 10, 2023

Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript

Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Dir more_horizontal

Predictive Oncology dramatically narrows its quarterly loss in latest financial results

By Proactive Investors
August 10, 2023

Predictive Oncology dramatically narrows its quarterly loss in latest financial results

Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quart more_horizontal

Predictive Oncology moves company headquarters to Pittsburgh

By Proactive Investors
July 18, 2023

Predictive Oncology moves company headquarters to Pittsburgh

Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylva more_horizontal

Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board

By Proactive Investors
June 27, 2023

Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board

Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisor more_horizontal

Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board

By Proactive Investors
June 20, 2023

Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board

Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB). The more_horizontal

Predictive Oncology forges key partnerships to drive oncology drug development in 1Q

By Proactive Investors
May 16, 2023

Predictive Oncology forges key partnerships to drive oncology drug development in 1Q

Predictive Oncology has updated investors on its use of artificial intelligence (AI) and machine learning and its extensive biorepository of tumor s more_horizontal

Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript

By Seeking Alpha
May 15, 2023

Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript

Predictive Oncology, Inc. (NASDAQ:POAI ) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Direct more_horizontal

Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board

By Proactive Investors
April 4, 2023

Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board

Predictive Oncology Inc. (NASDAQ:POAI) announced the appointment of Dr. Christoph Reinhard to its scientific board to serve alongside other key though more_horizontal


Search within

Pages Search Results: